ADMA Biologics saw its IBD SmartSelect Composite Rating jump to 96 Tuesday, up from 94 the day before.
The new rating shows the stock is outpacing 96% of all stocks when it comes to the most important stock-picking criteria. Winning stocks often have a 95 or higher rating in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.
ADMA Biologics is now out of buy range after breaking out from a 4.07 entry in a cup with handle.
Discover The 3 Keys To Successful Stock Investing
The stock earns an 81 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 81% of all stocks.
Its Accumulation/Distribution Rating of D shows moderate selling by institutional investors over the last 13 weeks. Look for the rating to improve to at least a C or better.
In Q3, the company posted 1,400% EPS growth. Top line growth was flat, matching the prior report's 78%.
ADMA Biologics earns the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals is the top-ranked stock within the group.
